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ABSTRACT
A large number of monoclonal antibodies (McAb) binding to
antigenic determinants of human tumour necrosis factor (TNF) were
prepared from two fusions of mouse myeloma NSO cells with spleen
cells from Balb/c mice immunized with highly purified recombinant(r)TNF. Several of these McAbs were highly neutralizing with
respect to the biological activity (cytotoxicity) of TNF manifested
in L-929 C1.10 cells. Antibody competition experiments suggested
the presence of at least two antigenic determinants on the rTNF
molecule through which binding of McAb effects neutralization of
biological activity. Some of these McAbs were shown to be suitable
for the development of immuoassays to quantify rTNF.
INTRODUCTION
Carswell et al (1) identified a cytotoxin (CTX) in the sera of
mice infected with Bacillus Calmette-Guerin (BCG) and subsequently
treated with endotoxin which they called TNF because of its ability
to induce selective tumour necrosis. It has been subsequently found
that activated macrophages are the major cellular source of TNF (2)
and that, in addition to its selective cytotoxicity, it has other
profound biological effects (3). Several of these effects have been
ascertained using highly purified rTNF derived from E.coli (4,5).
The availability of TNF-specific neutralising antibodies has also
aided elucidation of the various biological properties of TNF(6-10). In this study we set out to prepare anti-human TNF mono-
clonal antibodies (McAbs), for which, to our knowledge, there are as
yet few reports on their actual preparation and characterization(11,12), in order to learn more about the antigenic structure of TNF
and to prepare reagents for TNF quantification by imrounoassay.
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MATERIALS AND METHODS
Antibody Preparation
Recombinant human TNF (BASF Knoll AG, Ludwigshafen, FRG;1.5x10^ units/mg protein) was u§ed in all studies. Polyclonal
antiserum was produced in rabbits immunised intramuscularly (im)
with lOOug rTNF in Freund's complete adjuvant (FCA) and subsequently
boosted at 4-6 week intervals with the same dose of rTNF in
incomplete Freund's adjuvant (IFA). Serum from successive bleeds
was tested in TNF-neutralisation assays (see below) and the most
potent serum samples combined and purified by ammonium sulphate
precipitation followed by gel filtration in Ultrogel ACA44 (LKB).
Anti-rTNF McAbs were prepared by the Köhler and Milstein (13)
technique following immunisation of young Balb/c mice with 50ug rTNF
in FCA (day 0, im), 50yg rTNF in IFA (day 28, im) and lOOug rTNF
intravenously 3 days (day 126 and 196) before fusions with NSO were
carried out. Hybridoma wells were screened by solution phase immuno-
precipitation tests (IPT) (14) using l25l-rTNF labelled by reaction
with Enzymobead reagent (Bio-Rad Laboratories, Richmond, CA, USA) to
preserve biological activity of rTNF. Hybridoma cells from positive
wells were cloned in semi-solid agar, anti-rTNF McAb producing
clones identified by 125l-rTNF IPT, recloned and subsequently
expanded for cryopreservation and ascitic fluid production. Immuno-
globulin subclass determination was carried out using standard
procedures.
TNF Cytotoxicity Assays
L929 C1.10 cell monolayers in microtitre trays were stained
after 24 h incubation in medium containing rTNF plus actinomycin D(AMD; lug/ml) with amido blue black (30 min; 0.05% in 0. IM sodium
acetate-9% acetic acid), fixed (10 min; 0.IM sodium acetate-9%
acetic acid-10% formaldehyde), dye re-extracted in 0.05M NaOH and
absorbances read at 620nm in a Titertek Multiskan. Titres were
interpolated from dose response curves, the end-point being defined
as the median absorbance or ODg20 on the scale of dye uptake measure-
ments that range between those of untreated cells (negative control)
and those killed with a high dose of rTNF (positive control). A
laboratory reference preparation of rTNF was was included in all
assays. To estimate the neutralizing capacity of rabbit polyclonal
anti-rTNF and anti-rTNF McAbs, serial antibody dilutions were first
incubated with rTNF, at a concentration just sufficient to kill all
of the L-929 C1.10 cells, in medium containing AMD for 2 h at 37°C.
These diluted antibody-rTNF mixtures were then transferred to pre-
formed L-929 Cl.10 monolayers and cytotoxicity assays processed as
described previously. Antibody neutralizing titre was defined as
the reciprocal of that antibody dilution giving the median ODg20
measurement on the scale of dye uptake measurements that range
between positive and negative controls.
Immunoassays to Quantify TNF
—,-
--_
(i) imunoradiometric assay (IRMA) This was adapted from a method
described by Sécher (15) for the quantification of human interferon
alpha (HuIFNrï). Briefly, 6.5mm diameter etched polystyrene beads
coated with purified rabbit polyclonal anti-rTNF or anti-rTNF McAb(lOOug protein per ml in PBS) were incubated with serial dilutions
of rTNF reference preparation for 4 h at 4°C, washed three times and
then incubated with 125I-2.33.G2 or 125I 2.101.23 anti-rTNF McAb,
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radioiodinated by the chloramine T method (16), for 16 h at 4°C.
The beads were re-washed and counted in an LKB gamma counter.
(ii) enzyme-linked immunosorbent assay (ELISA) Purified rabbit
polyclonal anti-rTNF diluted 1:30 in PBS was coated on U-bottomed
polyvinyl chloride (PVC) microtitre plates (Dynatech), 50ul/well,
for 2 h at 37°C. Remaining sites in wells were blocked with 2%
BSA-PBS, 150ul per well, overnight at 4°C. Excess antibodies and
blocking buffer were then removed and wells washed 4 times with
0.05% Tween 20 (TW20)-PBS. Following the last wash, serial
dilutions of rTNF laboratory reference preparation, 50ul per well,
were added and incubated at 37°C for 1 h. Wells w,ere washed again 4
times with TW20-PBS followed by (a) addition of purified anti-rTNF
McAb, 1:100 in 2% BSA-PBS, 50pl/well, and incubation for 1 h at
37°C, (b) washing with TW20-PBS and addition of biotinylated sheep
anti-mouse immunoglobulin (Amersham International, UK), 1:500 in 2%
BSA-PBS, 50ul/well and incubation for 1 h at 37°C, (c) washing with
TW20-PBS and addition of streptavidin biotinylated horseradish
peroxidase complex (Amersham International, UK), 1:500 in 2%
BSA-PBS, 50yl/well and incubation for 30 min at 37°C, (d) washing
with TW20-PBS (twice) and 0.1M citrate/phosphate buffer, pH 5.0,(twice) and addition of substrate, orthophenylenediamine (OPD),
lmg/ml, in 0.IM citrate/phosphate buffer, pH 5.0, containing 0.006%
hydrogen peroxide (H2O2). Colour (yellow) was developed in the dark
for 30 min at room temperature and the reaction terminated by
addition of 50ul IM H2SO4 to each well. Optical densities were read
at 450nm in a Titertek Multiskan.
RESULTS AND DISCUSSION
Screening of two fusions by 125I-rTNF IPT showed that 90 of 760
wells contained anti-rTNF McAb-secreting hybridomas. Only about 15%
of these produced supernatants with significant neutralising
capacity against the cytotoxicity of rTNF. Some 27 of the 90
positives were cloned, with emphasis being placed on obtaining the
most potent neutralising McAbs. This process yielded 24 stable
hybridoma clones, 13 of which, when grown as ascites, produced
highly neutralising anti-rTNF McAbs (Table 1). The latter were of
comparable potency to rabbit polyclonal anti-rTNF which titred at
24000 nu/ml. All of the anti-rTNF McAbs so far tested, whether of
high or low neutralising capacity, were mouse IgGi subclass.
2.33.G2 and 3.101.23 anti-rTNF McAbs were purified from ascitic
fluid by protein A-sepharose chromatography (17) and labelled with125]- using the chloramine-T method (16). These radio-iodinated
McAbs were used in antibody competition experiments (Table 1) which
showed that anti-rTNF McAbs could be segregated into three broad
groups (Table 1), suggesting the existence of three or more
antigenic determinants or epitopes in the rTNF molecule. Highly
neutralising anti-rTNF McAbs were divided between the epitope
recognised by 2.33.G2 and that recognised by 3.101.23 (Table 1),
whilst the majority of low and non-neutralising McAbs, which did not
compete out the binding of either radio-iodinated McAb, presumably
bound to one or more different epitopes. Neutralisation of rTNF
cytotoxicity probably occurs because antibody-binding sterically
inhibits rTNF molecules attaching to their cell surface receptors.
Alternatively, that such neutralisation can occur through McAbs
binding to two or more separate epitopes suggests that two or more
distinct areas or sites on the rTNF molecule might be necessary for
receptor binding.
L-cell cytotoxicity assays for rTNF are quite easily performed,
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TABLE 1 NEUTRALISATION OF rTNF BY MONOCLONAL ANTIBODIES AND EPITOPE
ANALYSIS OF rTNFf
Epitope 1(defined by
binding of125I-2.33.G2)
McAb nu/ml
Epitope 2(defined by
binding of125I-3.101.23)
McAb nu/ml
Other epitopes
(not recognised
by either125 I-2.33.G2 or
-3.101.23
McAb nu/ml
33. G2
178.B8
179.F9
6.10
6.35
22.14
13.7*
27.2*
34.16*
51.17*
129.16*
24000
12000
24000
8000
960
960
10000
12000
80
12000
12000
3.88.2
3.88.34
3.101.23
3.D1.11
3.C9.12*
24000
56000
24000
12000
32000
28.C6
49.20
76.22
165.48
167.24
176.17
181.11
E5.23
1500
80
80
320
390
60
<10
<10
t Polyvinyl chloride microtitre plates were coated with rabbit
polyclonal anti-rTNF as described for ELISA. Following washing,
rTNF, 10^u/ml, was added, 50ul/well, to all wells and incubated for
1 h at 37°C. Wells were then washed thoroughly with TW20-PBS and
anti-rTNF McAbs as supernatant culture fluid or dilutions of ascitic
fluid added to the plate, 50ul/well, and incubated for 1 h at 37°C.
Wells were again washed thoroughly and theh the competing  '-"i-anti-
rTNF McAb added to all wells (50ul containing 1-2x10^ cpm/well).
Following further incubation for 1 h at 37°C and washing, wells were
cut from the plate with a hot wire and counted in an LKB gamma
counter. Negative control (no competition), 4x10^ cpm; positive
control (full competition, eg 125I-2.33.G2 against cold 2.33.G2)2xl02 cpm.
* Indicates that these McAbs partially compete binding of radio-
iodinated anti-rTNF McAbs
nu/ml
-
neutralising units per ml
but nevertheless tend to produce variable results. For instance,
purified rTNF (lmg/ml) titred at 5x10? units/ml, somewhat higher
than the manufacturer's estimate, in our L-929 C1.10 cells. Immuno-
assays, and in particular IRMA, have proved to be valuable
alternative assays for many biologically active proteins, eg
interferons (15,18). Using a method previously described for HuIFN"(15), rTNF-specific polyclonal antibodies attached to etched
polystyrene beads were first incubated with rTNF (0.1-5000 units/ml;
2-105pg/ml) and secondly with 125I-anti-rTNF McAb. Typical
calibration curves, plotted on a log^n-log^n basis, that were
generated with 125I-2.33.G2 or 125I-3.101.23 in these IRMA are shown
in Fig 1(A). The detection limit of both IRMA was 1 unit (20pg)/ml
and calibration curves were linear in the range 1-1000 units/ml.
Based on our epitope analysis or rTNF, IRMA were also constructed
with different combinations of mutually compatible anti-rTNF McAb
pairs. Of many combinations tested, 3.6.10 rTNF McAb in combination
with l25I 3.101.23 rTNF McAb (Fig 1(A)) or 2.28.C6 in combination
with l2^! 3.101.23 (not shown) produced the most sensitive IRMA with
calibration curves showing linearity in the range 1-2500 units/ml.
An ELISA constructed with rabbit polyclonal anti-rTNF as first
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antibody, 2.33.G2 anti-rTNF McAb as second antibody, and
biotinylated anti-mouse Ig plus streptavidin biotinylated horse-
radish peroxidase complex (Amersham International) as amplifying
layers on the sandwich assay was also reasonably sensitive for rTNF.
A typical calibration curve is shown in Fig KB). The detection
Figure 1(A). Calibration curves generated in IRMA with serial
two-fold dilutions of purified rTNF (1-5000 units/ml) using rabbitpolyclonal anti-rTNF on the bead and l25i- 3.101.23,«-», rabbit
polyclonal anti-rTNF on the Dead and 125I-2.33.G2,  - , and
3.6.10 anti-rTNF McAb on the bead and 125I-3 .101. 23
,
*-* 
.
(B) Calibration curve generated in ELISA with serial two-fold
dilutions of purified rTNF (1-5000 units/ml) using rabbit polyclonal
anti-rTNF on the well and 2.33.G2 anti-rTNF McAb as second antibody,
 - 
.
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limit was approximately 4 units/ml and the calibration curve linear
in the range 10-1000 units/ml. Purified 2.33.G2 anti-rTNF McAb
could be substituted by other neutralizing anti-rTNF McAbs but
non-neutralizing anti-rTNF McAbs were generally less effective (data
not shown) for ELISA. Both IRMA and ELISA for rTNF were specific
for TNF; neither type of immunoassay detected rLT (Genentech Inc) up
to concentrations as high as 5x10^ units/ml. The high degree of
specificity of these IRMA and ELISA for TNF and the development of
equivalent immunoassays for LT (Meager, A., in preparation) will
allow separate measurement of TNF and LT where these occur together
in biological fluids. This is not now possible using conventional
bioassays since the biological properties of TNF and LT appear to be
indistinguishable.
A great deal of new information about the structure and
functions of TNF has accumulated since the cloning of TNF cDNA(4,5). Newly recognised functions of TNF are still being reported,(eg 19) and more must be learned about the role of TNF in immune
regulation and inflammatory reactions. The anti-rTNF McAbs reported
in this study should prove useful for definitive studies on the
biological activities of TNF as well as for their application for
immunoassays and further epitope analysis.
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